Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 11:05AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

HAEMATOLOGY

BLOOD GROUP (ABO) AND RH FACTOR TYPING

ABO GROUP *by SLIDE AGGLUTINATION*	O		
RH FACTOR TYPE *by SLIDE AGGLUTINATION*	POSITIVE		

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 10:20PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

GLYCOSYLATED HAEMOGLOBIN (HBA1C)

GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	4.6	%	4.0 - 6.4
ESTIMATED AVERAGE PLASMA GLUCOSE *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	85.32	mg/dL	60.00 - 140.00

INTERPRETATION:

AS PER AMERICAN DIABETES ASSOCIATION (ADA):		
REFERENCE GROUP	**GLYCOSYLATED HEMOGLOGIB (HBAIC) in %**	
Non diabetic Adults >= 18 years	<5.7	
At Risk (Prediabetes)	5.7 – 6.4	
Diagnosing Diabetes	>= 6.5	
Therapeutic goals for glycemic control	**Age > 19 Years**	
	Goals of Therapy:	< 7.0
	Actions Suggested:	>8.0
	Age < 19 Years	
	Goal of therapy:	<7.5

COMMENTS:

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients.

2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3.Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropiate.

4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications

5.Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution , given the pathological processes including anemia,increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 12/Nov/2024 10:20AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

HAEMOGLOBIN - HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HB-HPLC)

Test Name	Value	Unit	Biological Reference interval
HAEMOGLOBIN VARIANTS			
HAEMOGLOBIN A0 (ADULT) *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	87.4	%	83.00 - 90.00
HAEMOGLOBIN F (FOETAL) *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	<0.8	%	0.00 - 2.0
HAEMOGLOBIN A2 *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	2	%	1.50 - 3.70
PEAK 3 *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	4.3	%	< 10.0
OTHERS-NON SPECIFIC *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	ABSENT	%	ABSENT
HAEMOGLOBIN S *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	NOT DETECTED	%	< 0.02
HAEMOGLOBIN D (PUNJAB) *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	NOT DETECTED	%	< 0.02
HAEMOGLOBIN E *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	NOT DETECTED	%	< 0.02
HAEMOGLOBIN C *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	NOT DETECTED	%	< 0.02
UNKNOWN UNIDENTIFIED VARIANTS *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	NOT DETECTED	%	< 0.02
GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD *by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)*	4.6	%	4.0 - 6.4
RED BLOOD CELLS (RBCS) COUNT AND INDICES			
HAEMOGLOBIN (HB) *by AUTOMATED HEMATOLOGY ANALYZER*	**10.8**^{L}	gm/dL	12.0 - 16.0
RED BLOOD CELL (RBC) COUNT *by AUTOMATED HEMATOLOGY ANALYZER*	4	Millions/cmm	3.50 - 5.00
PACKED CELL VOLUME (PCV) *by AUTOMATED HEMATOLOGY ANALYZER*	**34.1**^{L}	%	37.0 - 50.0
MEAN CORPUSCULAR VOLUME (MCV) *by AUTOMATED HEMATOLOGY ANALYZER*	85.3	fL	80.0 - 100.0
MEAN CORPUSCULAR HAEMOGLOBIN (MCH) *by AUTOMATED HEMATOLOGY ANALYZER*	**26.9**^{L}	pg	27.0 - 34.0

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 12/Nov/2024 10:20AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC) *by AUTOMATED HEMATOLOGY ANALYZER*	**31.5**^{L}	g/dL	32.0 - 36.0
RED CELL DISTRIBUTION WIDTH (RDW-CV) *by AUTOMATED HEMATOLOGY ANALYZER*	14.3	%	11.00 - 16.00
RED CELL DISTRIBUTION WIDTH (RDW-SD) *by AUTOMATED HEMATOLOGY ANALYZER*	45.4	fL	35.0 - 56.0
OTHERS			
NAKED EYE SINGLE TUBE RED CELL OSMOTIC FRAGILITY TEST *by SINGLE RED CELL OSMOTIC FRAGILITY*	NEGATIVE (-ve)		NEGATIVE (-ve)
MENTZERS INDEX *by CALCULATED*	21.33	RATIO	BETA THALASSEMIA TRAIT: < 13.0 IRON DEFICIENCY ANEMIA: >13.0
INTERPRETATION	THE ABOVE FINDINGS ARE SUGGESTIVE OF NORMAL HAEMOGLOBIN CHROMATOGRAPHIC PATTERN		

INTERPRETATION:

The Thalassemia syndromes, considered the most common genetic disorder worldwide, are a heterogenous group of mandelian disorders, all characterized by a lack of/or decreased synthesis of either the alpha-globin chains (alpha thalassemia) or the beta-globin chains (beta thalassemia) of haemoglobin.

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC):

1.HAEMOGLOBIN VARIANT ANALYSIS, BLOOD- High Performance liquid chromatography (HPLC) is a fast & accurate method for determining the presence and for quatitation of various types of normal haemoglobin and common abnormal hb variants, including but not limited to Hb S, C, E, D and Beta –thalassemia.
2.The diagnosis of these abnormal haemoglobin should be confirmed by DNA analysis.
3.The method use has a limited role in the diagnosis of alpha thalassemia.
4.Slight elevation in haemoglobin A2 may also occur in hyperthyroidism or when there is deficiency of vitamin b12 or folate and this should be istinguished from inherited elevation of HbA2 in Beta- thalassemia trait.

NAKED EYE SINGLE TUBE RED CELL OSMOTIC FRAGILITY TEST (NESTROFT):

1.It is a screening test to distinguish beta thalassemia trait. Also called as Naked Eye Single Tube Red Cell Osmotic Fragility Test.
2.The test showed a sensitivity of 100%, specificity of 85.47%, a positive predictive value of 66% and a negative predictive value of 100%.
3.A high negative predictive value can reasonably rule out beta thalassemia trait cases. So, it should be adopted as a screening test for beta thalassemia trait, as it is not practical or feasible to employ HbA2 in every case of anemia in childhood.

MENTZERS INDEX:

1.The Mentzer index, helpful in differentiating iron deficiency anemia from beta thalassemia. If a CBC indicates microcytic anemia, the Mentzer index is said to be a method of distinguishing between them.
2.If the index is less than 13, thalassemia is said to be more likely. If the result is greater than 13, then iron-deficiency anemia is said to be more likely.
3.The principle involved is as follows: In iron deficiency, the marrow cannot produce as many RBCs and they are small (microcytic), so the RBC

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 12/Nov/2024 10:20AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

count and the MCV will both be low, and as a result, the index will be greater than 13. Conversely, in thalassemia, which is a disorder of globin synthesis, the number of RBC's produced is normal, but the cells are smaller and more fragile. Therefore, the RBC count is normal, but the MCV is low, so the index will be less than 13.

NOTE: In practice, the Mentzer index is not a reliable indicator and should not, by itself, be used to differentiate. In addition, it would be possible for a patient with a microcytic anemia to have both iron deficiency and thalassemia, in which case the index would only suggest iron deficiency.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 12:20PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

CLINICAL CHEMISTRY/BIOCHEMISTRY

IRON PROFILE

IRON: SERUM *by FERROZINE, SPECTROPHOTOMETRY*	38.81	µg/dL	37.0 - 145.0
UNSATURATED IRON BINDING CAPACITY (UIBC) :SERUM *by FERROZINE, SPECTROPHOTOMETERY*	276.49	µg/dL	150.0 - 336.0
TOTAL IRON BINDING CAPACITY (TIBC) :SERUM *by SPECTROPHOTOMETERY*	315.3	µg/dL	230 - 430
%TRANSFERRIN SATURATION: SERUM *by CALCULATED, SPECTROPHOTOMETERY (FERENE)*	**12.31**^{L}	%	15.0 - 50.0
TRANSFERRIN: SERUM *by SPECTROPHOTOMETERY (FERENE)*	223.86	mg/dL	200.0 - 350.0

INTERPRETATION:-

VARIABLES	*ANEMIA OF CHRONIC DISEASE*	*IRON DEFICIENCY ANEMIA*	*THALASSEMIA α/β TRAIT*
SERUM IRON:	Normal to Reduced	Reduced	Normal
TOTAL IRON BINDING CAPACITY:	Decreased	Increased	Normal
% TRANSFERRIN SATURATION:	Decreased	Decreased < 12-15 %	Normal
SERUM FERRITIN:	Normal to Increased	Decreased	Normal or Increased

IRON:
1.Serum iron studies is recommended for differential diagnosis of microcytic hypochromic anemia.i.e iron deficiency anemia, zinc deficiency anemia,anemia of chronic disease and thalassemia syndromes.
2. It is essential to isolate iron deficiency anemia from Beta thalassemia syndromes because during iron replacement which is therapeutic for iron deficiency anemia, is severely contra-indicated in Thalassemia.

TOTAL IRON BINDING CAPACITY (TIBC):
1.It is a direct measure of protein transferrin which transports iron from the gut to storage sites in the bone marrow.

% TRANSFERRIN SATURATION:
1.Occurs in idiopathic hemochromatosis and transfusional hemosiderosis where no unsaturated iron binding capacity is available for iron mobilization. Similar condition is seen in congenital deficiency of transferrin.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 11:36AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

ENDOCRINOLOGY

THYROID FUNCTION TEST: TOTAL

TRIIODOTHYRONINE (T3): SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)*	0.963	ng/mL	0.35 - 1.93
THYROXINE (T4): SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)*	8.37	µgm/dL	4.87 - 12.60
THYROID STIMULATING HORMONE (TSH): SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)*	1.614	µIU/mL	0.35 - 5.50

3rd GENERATION, ULTRASENSITIVE

INTERPRETATION:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%.Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4)and triiodothyronine (T3).Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction(hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	T3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

LIMITATIONS:-

1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG),and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests.
2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs (e.g.: phenytoin , salicylates).
3. Serum T4 levels in neonates and infants are higher than values in the normal adult , due to the increased concentration of TBG in neonate serum.
4. TSH may be normal in central hypothyroidism , recent rapid correction of hyperthyroidism or hypothyroidism , pregnancy , phenytoin therapy.

TRIIODOTHYRONINE (T3)		THYROXINE (T4)		THYROID STIMULATING HORMONE (TSH)	
Age	**Refferance Range (ng/mL)**	**Age**	**Refferance Range (µg/dL)**	**Age**	**Reference Range (µIU/mL)**
0 - 7 Days	**0.20 - 2.65**	**0 - 7 Days**	**5.90 – 18.58**	**0 - 7 Days**	**2.43 - 24.3**
7 Days - 3 Months	**0.36 - 2.59**	**7 Days - 3 Months**	**6.39 - 17.66**	**7 Days - 3 Months**	**0.58 - 11.00**
3 - 6 Months	**0.51 - 2.52**	**3 - 6 Months**	**6.75 – 17.04**	**3 Days – 6 Months**	**0.70 - 8.40**
6 - 12 Months	**0.74 - 2.40**	**6 - 12 Months**	**7.10 – 16.16**	**6 – 12 Months**	**0.70 - 7.00**

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 11:36AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name			Value	Unit	Biological Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 – 5.50
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35– 5.50
RECOMMENDATIONS OF TSH LEVELS DURING PREGNANCY (µIU/mL)					
1st Trimester			0.10 – 2.50		
2nd Trimester			0.20 – 3.00		
3rd Trimester			0.30 – 4.10		

INCREASED TSH LEVELS:

1.Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
2.Hypothyroid patients receiving insufficient thyroid replacement therapy.
3.Hashimotos thyroiditis
4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.
5.Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

DECREASED TSH LEVELS:

1.Toxic multi-nodular goiter & Thyroiditis.
2.Over replacement of thyroid hormone in treatment of hypothyroidism.
3.Autonomously functioning Thyroid adenoma
4.Secondary pituitary or hypothalamic hypothyroidism
5.Acute psychiatric illness
6.Severe dehydration.
7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.
8.Pregnancy: 1st and 2nd Trimester

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 01:50PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

BETA HCG - TOTAL (QUANTITATIVE): MATERNAL

BETA HCG TOTAL, PREGNANCY MATERNAL: SERUM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	**23400.24^{H}**	mIU/mL	< 5.0

INTERPRETATION:

MEN:	mIU/ml	< 2.0
NON PREGNANT PRE-MENOPAUSAL WOMEN:	mIU/ml	< 5.0
MENOPAUSAL WOMEN:	mIU/ml	< 7.0
BETA HCG EXPECTED VALUES IN ACCORDANCE TO WEEKS OF GESTATIONAL AGE		
WEEKS OF GESTATION	Unit	Value
4-5	mIU/ml	1500 -23000
5-6	mIU/ml	3400 - 135300
6-7	mIU/ml	10500 - 161000
7-8	mIU/ml	18000 - 209000
8-9	mIU/ml	37500 - 219000
9-10	mIU/ml	42800 - 218000
10-11	mIU/ml	33700 - 218700
11-12	mIU/ml	21800 - 193200
12-13	mIU/ml	20300 - 166100
13-14	mIU/ml	15400 - 190000
2rd TRIMESTER	mIU/ml	2800 - 176100
3rd TRIMESTER	mIU/ml	2800 - 144400

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 01:50PM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

1.hCG is a Glycoprotein with alpha and beta chains. Beta subunit is specific to hCG.
2.It is largely secreted by trophoblastic tissue. Small amounts may be secreted by fetal tissues and by the adult ant pituitary.
INCREASED :
1.Pregnancy
2.Gestationalsite & Non gestational trophoblastic neoplasia.
3.In mixed germ cell tumors.

SIGNIFICANTLY HIGHER THAN EXPECTED LEVEL:

1.Multiple pregnancies & High risk molar pregnancies are usually associated with levels in excess of one lac mIU/ml.
2.Erythroblastosis fetalis & Downs syndrome.

DECREASED:

1.Ectopic pregnancy.
2.Intra-uterine fetal death.

NOTE:

1.The test becomes positive 7-9 days after the midcycle surge that precedes ovulation (time of blastocyst implantation). Blood levels rise rapidly after this and double every 1.4 - 2 days.
2.Peak values are usually seen at 60-80 days of LMP. The levels then begin to taper and ebb out around the 20th week. These low levels are then maintained throughout pregnancy.
3.Doubling time: In intra-uterine pregnancy, serum hCG levels increase by approximately 66% every 48 hrs.Inappropriately rising serum hCG levels are suggestive of dying or ectopic pregnancy.

CAUTION:

Spuriously high levels (Phantom hCG) may be seen in presence of heterophilic antibodies (found in some normal people). If persistently raised levels are seen in a non-pregnant patient with no evidence of other obvious causes for such an increase a urine hCG assay may help confirm presence of the heterophile antibodies.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 11:36AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

PROGESTERONE

PROGESTERONE: SERUM *by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)*	23.21	ng/mL	FEMALE FOLLICULAR PHASE: 0.10 - 1.50 FEMALE OVULATORY PHASE: 0.40 - 3.00 FEMALE LUTEAL PHASE: 1.20 - 18.80 POST MENOPAUSAL: < 1.40 MALES: < 2.80

INTERPRETATION:

EXPECTED VALUES OF PROGESTERONE DURING PREGNANCY	
	UNITS (ng/mL)
First trimester (0 - 12 Wweeks)	15.8 - 46.0
Second trimester (13 - 28 Wweeks)	15.6 - 74.0
Third trimester (29 - 40 Wweeks)	45.0 - 143.0
Post Menopausal	< 1.40

1. Progesterone is produced by the adrenal glands, corpus luteum, and placenta.
2. After ovulation, there is a significant rise in serum Progesterone levels as the corpus luteum begins To produce progesterone in increasing amounts. This causes changes in the uterus, preparing it for implantation of a fertilized egg. If implantation occurs, the trophoblast begins to secrete human chorionic gonadotropin, which maintains the corpus luteum and its secretion of progesterone. If there is no implantation, the corpus luteum degenerates and circulating progesterone levels decrease rapidly, reaching follicular phase levels about 4 days before the next menstrual period.

The test is indicated for:

1. Ascertaining whether ovulation occurred in a menstrual cycle
2. Evaluation of placental function in pregnancy
3. Workup of some patients with adrenal or testicular tumors

NOTE:

In patients receiving therapy with high biotin doses (ie, >5 mg/day), no specimen should be drawn until at least 8 hours after the last biotin administration.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 11/Nov/2024 11:44AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

IMMUNOPATHOLOGY/SEROLOGY

ANTI THYROID PEROXIDASE (TPO/AMA) ANTIBODIES

ANTI TPO/AMA ANTIBODIES: SERUM *by CLIA (CHEMILUMINESCENCE IMMUNOASSAY)*	2.01	IU/mL	0.00 - 10.0 DIABETES (II): < 25.0

INTERPRETATION:

1. Thyroperoxidase (TPO) is an enzyme involved inthyroid hormone synthesis, catalyzing the oxidation of iodide on tyrosine residues in thyroglobulin for the synthesis of triiodothyronine and thyroxine (tetraiodothyronine).
2. TPO is a membrane-associated hemo glycoprotein expressed only in thyrocytes and is one of the most important thyroid gland antigens.
3. Anti-TPO is technically superior and a more specific method for measuring thyroid auto-antibodies , It is especially useful in patients presenting with subclinical hypothyroidism where TSH is elevated but Free T4 levels are normal.

INCREASED LEVELS (Autoimmune thyroid disease):

1. Hashimoto thyroiditis.
2. Idiopathic myxedema.
3. Graves disease
4. Post-partum thyroiditis.
5. Primary hypothyroidism due to Hashimoto thyroiditis.

NOTE:

1. The highest TPO antibody levels are observed in patients suffering from Hashimoto thyroiditis. In this disease, the prevalence of TPO antibodies is about 90% of cases, confirming the autoimmune origin of the disease.
2. These auto-antibodies also frequently occur (60%-80%) in the course of Graves disease.
3. In patients with subclinical hypothyroidism, the presence of TPO antibodies is associated with an increased risk of developing overt hypothyroidism.

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Dr. Vinay Chopra
MD (Pathology & Microbiology)
Chairman & Consultant Pathologist

Dr. Yugam Chopra
MD (Pathology)
CEO & Consultant Pathologist

NAME	**: Dr. PALLAVI**		
AGE/ GENDER	: 31 YRS/FEMALE	**PATIENT ID**	: 1667892
COLLECTED BY	:	**REG. NO./LAB NO.**	**: 012411110032**
REFERRED BY	:	**REGISTRATION DATE**	: 11/Nov/2024 10:20 AM
BARCODE NO.	: 01520560	**COLLECTION DATE**	: 11/Nov/2024 10:52AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	**REPORTING DATE**	: 13/Nov/2024 10:21AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, AMBALA CANTT		

Test Name	Value	Unit	Biological Reference interval

MICROBIOLOGY

CULTURE AEROBIC BACTERIA AND ANTIBIOTIC SENSITIVITY: URINE

CULTURE AND SUSCEPTIBILITY: URINE

DATE OF SAMPLE	11-11-2024
SPECIMEN SOURCE	URINE
INCUBATION PERIOD *by AUTOMATED BROTH CULTURE*	48 HOURS
CULTURE *by AUTOMATED BROTH CULTURE*	STERILE
ORGANISM *by AUTOMATED BROTH CULTURE*	NO AEROBIC PYOGENIC ORGANISM GROWN AFTER 48 HOURS OF INCUBATION AT 37*C

AEROBIC SUSCEPTIBILITY: URINE

INTERPRETATION:

1. In urine culture and sensitivity, presence of more than 100,000 organism per mL in midstream sample of urine is considered clinically significant. However in symptomatic patients , a smaller number of bacteria (100 to 10000/mL) may signify infection.
2. Colony count of 100 to 10000/ mL indicate infection, if isolate from specimen obtained by suprapubic aspiration or “in-and-out” catheterization or from patients with indwelling catheters.

SUSCEPTIBILITY:

1. A test interpreted as **SENSTITIVE** implies that infection due to isolate may be appropriately treated with the dosage of an antimicrobial agent recommended for that type of infection and infecting species, unless otherwise indicated..
2. A test interpreted as **INTERMEDIATE** implies that the” Infection due to the isolate may be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used”.
3. A test interpreted as **RESISTANT** implies that the “isolates are not inhibited by the usually achievable concentration of the agents with normal dosage, schedule and/or fall in the range where specific microbial resistance mechanism are likely (e.g. beta-lactamases), and clinical efficacy has not been reliable in treatment studies.

CAUTION:

Conditions which can cause a false Negative culture:

1. Patient is on antibiotics. Please repeat culture post therapy.
2. Anaerobic bacterial infection.
3. Fastidious aerobic bacteria which are not able to grow on routine culture media.
4. Besides all these factors, at least in 25-40 % of cases there is no direct correlation between in vivo clinical picture.
5. Renal tuberculosis to be confirmed by AFB studies.

*** End Of Report ***

DR.VINAY CHOPRA
CONSULTANT PATHOLOGIST
MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA
CONSULTANT PATHOLOGIST
MBBS , MD (PATHOLOGY)

Patient report

Bio-Rad	DATE: 11/11/2024
D-10	TIME: 10:22 AM
S/N: #DJ6F040603	Software version: 4.30-2
Sample ID:	01520560
Injection date	11/11/2024 10:15 AM
Injection #: 9	Method: HbA2/F
Rack #: ---	Rack position: 9



Peak table - ID: 01520560

Peak	R.time	Height	Area	Area %
A1a	0.20	8992	39363	0.9
A1b	0.29	10824	39702	0.9
F	0.47	1741	22989	< 0.8 *
LA1c/CHb-1	0.73	4859	42397	0.9
A1c	0.92	13610	146623	4.6
P3	1.53	27193	196961	4.3
A0	1.70	658379	4027035	87.4
A2	3.34	5846	89937	2.0
Total Area:	4605007 *			

Concentration:	%
F	< 0.8 *
A1c	4.6
A2	2.0